Toxicology Letters 1993: Vol 68 Index

4 Pages·1993·0.64 MB·English

Toxicology Letters, 68 (1993) 333-334
Elsevier Science Publishers B.V.
AUTHOR INDEX VOL. 68 (1993)
Ali, B., see Siddiqui, A., 301
based pharmacokinetic (PBPK) model parame-
Andersen, M.E., see Mills, J.J., 177
ters and their effects on PBPK model predic-
Arias, R.N. and de Peretti, A.F., Effects of 2,4-
tions in a risk assessment for perchloroethylene
dichlorophenoxyacetic acid on Rhizobium sp.
(PCE), 131
growth and characterization of its transport,
Gibson, G.G., Peroxisome proliferators: Para-
267
digms and prospects, 193
Grabau, J.H., Animal issues and society, 51
Brashear, W.T., see Dodd, D.E., 37
Green, S., Regulatory agency considerations and
Bull, R.J., Templin, M., Larson, J.L. and Stevens,
requirements for validation of toxicity test al-
D.K., The role of dichloroacetate in the hepa-
ternatives, 119
tocarcinogenicity of trichloroethylene, 203
Greene, R.J., see Gearhart, J.M., 131
Caldwell, D.J., Use of alternative endpoints with
Hancock, B.L., see Channel, S.R., 213
the UPitt I] method for assessing the toxicity of
Hansen, L.G., see Ness, D.K., 311
smoke, 241
Harkema, J.R. and Hotchkiss, J.A., Ozone- and
Clewell III, H.J., see Gearhart, J.M., 131
endotoxin-induced mucous cell metaplasias in
Clewell III, H.J., Coupling of computer modeling
rat airway epithelium: Novel animal models to
with in vitro methodologies to reduce animal
study toxicant-induced epithelial transforma-
usage in toxicity testing, 101
tion in airways, 25]
Channel, S.R. and Hancock, B.L., Application of
Hiller, R.G., see Wilkinson, J.M., 285
kinetic models to estimate transit time through
Hotchkiss, J.A., see Harkema, J.R., 251
cell cycle compartments, 213
Huang, Y.-S. and Sultatos, L.G., Glutathione-de-
pendent biotransformation of methyl parathi-
DelRaso, N.J., In vitro methodologies for en-
on by mouse liver in vitro, 275
hanced toxicity testing, 91
Dodd, D.E., Brashear, W.T. and Vinegar, A..,
Kienholz, E., see Siblerud, R.L., 307
Metabolism and pharmacokinetics of selected
Kolmer, J.W., Current DoD policy on use of ani-
Halon replacement candidates, 37 -
mals in research, 59
Dodd, D.E., see McDougal, J.N., 31
Komulainen, H., see Risto, L., 325
Kucharz, E.J. and Olezyk, K., Influence of chron-
Fisher, J.W., Estimating the risks of liver and lung
ic intoxication with selenium on collagen and
cancer in humans exposed to trichloroethylene
elastin content in tissues of rat, 295
using a physiological model, 127
Fisher, J.W., see Gearhart, J.M., 131
Larson, J.L., see Bull, R.J., 203
Flemming, C.D., see Gearhart, J.M., 131
Li, K., see Wilkinson, J.M., 285
Frazier, J.M., In vitro models for toxicological
research and testing, 73
Mahle, D.A., see Gearhart, J.M., 131
Frederick, C.B., Limiting the uncertainty in risk
McDougal, J.N. and Dodd, D.E., Air Force ap-
assessment by the development of physiologi-
proach to risk assessment for Halon replace-
cally based pharmacokinetic and pharmacody-
ments, 31
namic models, 159
McMaster, S.B., Developmental toxicity, repro-
ductive toxicity, and neurotoxicity as regulato-
Gearhart, J.M., Mahle, D.A., Greene, R.J., Seck-
ry endpoints, 225
el, C.S., Flemming, C.D., Fisher, J.W. and Cle-
Mills, J.J. and Andersen, M.E., Dioxin hepatic
well III, H.J., Variability of physiologically
334
carcinogenesis: Biologically motivated model- Schantz, S.L., see Ness, D.K., 311
ing and risk assessment, 177 Seckel, C.S., see Gearhart, J.M., 131
Morehouse, E.T., Overview — Air Force policy on Siblerud, R.L., Kienholz, E. and Motl, J., Evi-
halons, 11 dence that mercury from silver dental fillings
Moshtaghian, J., see Ness, D.K., 311 may be an etiological factor in smoking, 307
Motl, J., see Siblerud, R.L., 307 Siddiqui, A., Ali, B. and Srivastava, S.P., Effect of
mancozeb on hepatic glutathione S-transferase
Ness, D.K., Schantz, S.L., Moshtaghian, J. and in rat, 301
Hansen, L.G., Effects of perinatal exposure to Srivastava, S.P., see Siddiqui, A., 301
specific PCB congeners on thyroid hormone Stevens, D.K., see Bull, R.J., 203
concentrations and thyroid histology in the rat, Sultatos, L.G., see Huang, Y.-S., 275
311
Templin, M., see Bull, R.J., 203
O'Flaherty, E.J., A pharmacokinetic model for Tilson, H.A., Neurobehavioral methods used in
chromium, 145 neurotoxicological research, 231
Olezyk, K., see Kucharz, E.J., 295 Trochimowicz, H.J., Industrial research on alter-
native fluorocarbons, 25
de Peretti, A.F., see Arias, R.N., 267
Pollard, I., see Wilkinson, J.M., 285 Vartiainen, T., see Risto, L., 325
Vinegar, A., see Dodd, D.E., 37
Risto, L., Vartiainen, T. and Komulainen, H.,
Formation of methemoglobin by 3-chloro-4- Walsh, D.A., see Wilkinson, J.M., 285
(dichloromethyl)-5-hydroxy-2(5H)-furanone, Wilkinson, J.M., Pollard, I., Walsh, D.A., Hiller,
MX, in rat erythrocytes in vitro, 325 R.G. and Li, K., Caffeine does not increase
Rowan, A.N., Formulation of ethical standards synthesis of heat shock proteins in rat embryos,
for use of animals in medical research, 63 285
Rubenstein, R., Human health and environment-
al toxicity issues for evaluation of halon re-
placements, 21
Toxicology Letters, 68 (1993) 335-336
Elsevier Science Publishers B.V.
SUBJECT INDEX VOL. 68 (1993)
Air Force halon uses, 11 Fluorocarbon alternatives, 25
Air Force Regulation 19-15, 11
Airway epithelium, 251 Glutathione, 275
Alternative end points, 241 Glutathione S-transferase, 301
Alternatives, 119 Growth factor, 177
Animal activists, 51
Animal issues, 51 Halon 1211, 37
Animal patents, 51 Halon replacement, 31
Animal research, 51, 63 Halon replacements, 11
Animal rights, 63, 51 Halon substitute, 21
Animal use, 51 HCFC-123, 37, 25
Animal welfare, 51 HCFC-124, 37, 25
Animals in research, 59 HCFC-142b, 37
Arsenate, 267 Hemoglobin, 325
Hepatocarcinogenicity, 193, 203
Behavioral toxicology, 231 Hepatocyte, 91
Biologically based risk assessment, 159 HFC-125, 25
HFC-134a, 25
Caffeine, 285 hsp 25, 285
Cancer risk assessment, 159 hsp 70, 285
Carcinogenesis, 213 hsp 90, 285
Cardiotoxicity, 21 Hydrochlorofluorocarbon, 37
Cell cycle, 213 Hydrochlorofluorocarbons, 25
Chemical risk assessment, 101 Hydrofluorocarbons, 25
Chloramphenicol, 267 Hydroxyproline, 295
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-
furanone, 325 In vitro, 91, 119, 73
Chromium, 145 In vitro methods, 101
Collagen, 295
Combustion toxicology, 241 Kinetic model, 213
Cytochrome P-450, 177
Cytochrome P4504 family, 193 Mancozeb, 301
2,4-D, 267 Mercury, 307
Methemoglobin, 325
Dental amalgam, 307 Methods, 91, 231
Department of Defense, 59 Methyl parathion, 275
Developmental toxicity, 225 Model, 177
Dichloroacetate, 203 Mucous cell metaplasia, 251
Elastin, 295 Neurotoxicity, 225
Endotoxin, 251 Neurotransmitter, 307
Ethics, 63 Nonmutagenic carcinogen, 193
Ethyl acrylate, 159
Organophosphate biotransformation, 275
Fire extinguishing, 21 Oxidative damage, 325
336
Ozone, 251 Smoke toxicity, 241
Smoking, 307
PBPK, 177 Sodium azide, 267
PBPK modeling, 101 Sodium selenite, 295
PCB, 311
Perchloroethylene, 131 TCDD, 177
Perfluorohexane, 37 Test guidelines, 225
Perinatal, 311 Tetrachloroethylene, 131
Peroxisome proliferator, 193 Thyroid, 311
Pharmacokinetic models, 31 Thyroxine, 311
Pharmacokinetics, 101 Tier-testing, 231
Physiological modeling, 101 Toxicity, 119
Physiologically based model, 145 Toxicity testing, 73
Physiologically based pharmacokinetic modeling, Trichloroacetate, 203
127 Trichloroethylene, 127, 203
Physiologically based pharmacokinetic (PBPK) Trifluoroacetic acid, 37
model, 131, 159 Triiodothyronine, 311
Tumor promotion, 177
Rat, 311, 145
Rat embryo, 285 Uncertainty in cancer risk assessment, 159
Rat liver, 301 UPitt II method, 241
Regulation, 59 Uptake, 267
Rhizobium, 267
Risk assessment, 127, 225, 31, 131 Validation, 119, 73
Screens, 91 Water chlorination, 325